Leerink Partnrs Estimates Sanofi FY2024 Earnings

Sanofi (NASDAQ:SNY - Free Report) - Investment analysts at Leerink Partnrs issued their FY2024 earnings estimates for shares of Sanofi in a report issued on Monday, January 27th. Leerink Partnrs analyst D. Risinger expects that the company will post earnings per share of $3.77 for the year. The consensus estimate for Sanofi's current full-year earnings is $3.82 per share. Leerink Partnrs also issued estimates for Sanofi's Q4 2024 earnings at $0.74 EPS, Q1 2025 earnings at $0.75 EPS, Q2 2025 earnings at $0.84 EPS, FY2025 earnings at $4.06 EPS, FY2026 earnings at $4.57 EPS, FY2027 earnings at $4.76 EPS and FY2028 earnings at $5.39 EPS.

Sanofi (NASDAQ:SNY - Get Free Report) last issued its quarterly earnings data on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.70. Sanofi had a net margin of 9.96% and a return on equity of 27.45%.

A number of other brokerages have also recently commented on SNY. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a "sell" rating to a "hold" rating in a report on Thursday. StockNews.com downgraded shares of Sanofi from a "buy" rating to a "hold" rating in a research note on Thursday, December 12th. Two analysts have rated the stock with a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Sanofi currently has an average rating of "Moderate Buy" and an average target price of $60.00.

Sanofi Trading Up 3.8 %

NASDAQ:SNY traded up $1.99 during trading hours on Thursday, reaching $54.14. 4,532,973 shares of the stock were exchanged, compared to its average volume of 2,650,813. Sanofi has a twelve month low of $45.22 and a twelve month high of $58.97. The business has a 50-day moving average of $48.99 and a two-hundred day moving average of $52.22. The company has a market capitalization of $137.41 billion, a price-to-earnings ratio of 27.62, a PEG ratio of 1.19 and a beta of 0.57. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17.

Institutional Trading of Sanofi

Institutional investors have recently modified their holdings of the stock. Franklin Resources Inc. increased its holdings in shares of Sanofi by 13.1% in the 3rd quarter. Franklin Resources Inc. now owns 3,407,452 shares of the company's stock valued at $208,106,000 after acquiring an additional 395,744 shares during the period. Natixis Advisors LLC increased its stake in Sanofi by 4.1% in the third quarter. Natixis Advisors LLC now owns 2,874,193 shares of the company's stock valued at $165,640,000 after purchasing an additional 114,133 shares during the period. Raymond James & Associates raised its holdings in shares of Sanofi by 4.8% in the third quarter. Raymond James & Associates now owns 2,819,348 shares of the company's stock valued at $162,479,000 after buying an additional 129,472 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Sanofi by 20.9% during the third quarter. JPMorgan Chase & Co. now owns 2,310,809 shares of the company's stock worth $133,172,000 after buying an additional 399,301 shares during the period. Finally, DAVENPORT & Co LLC grew its holdings in shares of Sanofi by 40.7% during the fourth quarter. DAVENPORT & Co LLC now owns 2,295,569 shares of the company's stock worth $110,715,000 after buying an additional 664,455 shares during the last quarter. Hedge funds and other institutional investors own 14.04% of the company's stock.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.